These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35514529)

  • 21. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
    Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life clinical use of natalizumab and fingolimod in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T
    Acta Neurol Scand; 2018 Feb; 137(2):181-187. PubMed ID: 29159801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
    Butzkueven H; Licata S; Jeffery D; Arnold DL; Filippi M; Geurts JJ; Santra S; Campbell N; Ho PR;
    BMJ Open; 2020 Oct; 10(10):e038861. PubMed ID: 33082194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.
    Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Cornelissen C; Ettle B;
    Mult Scler Relat Disord; 2020 Apr; 39():101893. PubMed ID: 31865273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
    Kalincik T; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Lechner-Scott J; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Solaro C; Grand'Maison F; Hupperts R; Prevost J; Sola P; Ferraro D; Terzi M; Butler E; Slee M; Kermode A; Fabis-Pedrini M; McCombe P; Barnett M; Shaw C; Hodgkinson S; Butzkueven H;
    Mult Scler; 2018 Oct; 24(12):1617-1626. PubMed ID: 28857680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
    Meca-Lallana J; Ayuso T; Martínez-Yelamos S; Durán C; Contreras Martín Y; Herrera Navarro N; Pérez Sempere A; Álvarez-Cermeño JC; Millán Pascual J; Meca-Lallana V; Romero Sevilla R; Ricart J
    Eur Neurol; 2020; 83(1):25-33. PubMed ID: 32187609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
    Bianco A; Patanella AK; Nociti V; Marti A; Frisullo G; Plantone D; De Fino C; Fetta A; Batocchi AP; Rossini PM; Mirabella M
    Eur Neurol; 2015; 73(1-2):57-65. PubMed ID: 25402749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Yeh WZ; Widyastuti PA; Van der Walt A; Stankovich J; Havrdova E; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout BI; Lechner-Scott J; Sola P; Skibina OG; Barnett M; Onofrj M; Sá MJ; McCombe PA; Grammond P; Ampapa R; Grand'Maison F; Bergamaschi R; Spitaleri DLA; Van Pesch V; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Gresle M; Uher T; Maimone D; Turkoglu R; Hupperts RM; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell RA; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis VG;
    Neurology; 2021 Jun; 96(24):e2989-e3002. PubMed ID: 33879599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ;
    PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab
    Puthenparampil M; Cazzola C; Zywicki S; Federle L; Stropparo E; Anglani M; Rinaldi F; Perini P; Gallo P
    Ther Adv Neurol Disord; 2018; 11():1756286418805713. PubMed ID: 30386435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Shaygannejad V; Mirmosayyeb O; Bagherieh S; Shaygan P; Ghajarzadeh M
    Int J Prev Med; 2023; 14():131. PubMed ID: 38449687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effectiveness of fingolimod in a Portuguese real-world population.
    Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
    Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.